CARAMIPHEN EDISYLATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	2C18H27NO2.C2H6O6S2
Molecular Weight	769.02
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

OS(=O)(=O)CCS(O)(=O)=O.CCN(CC)CCOC(=O)C1(CCCC1)C2=CC=CC=C2.CCN(CC)CCOC(=O)C3(CCCC3)C4=CC=CC=C4

InChI

InChIKey=BANIDACEBXZGNK-UHFFFAOYSA-N

InChI=1S/2C18H27NO2.C2H6O6S2/c2*1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16;3-9(4,5)1-2-10(6,7)8/h2*5-7,10-11H,3-4,8-9,12-15H2,1-2H3;1-2H2,(H,3,4,5)(H,6,7,8)

HIDE SMILES / InChI

Description

Caramiphen is a muscarinic M1 acetylcholine receptor antagonist, which was used for the treatment of Parkinson Disease and cough, but then there using were discontinued. Caramiphen is also used in local anesthesia, and effect could be achieved through the suppression of voltage-gated Na⁺ currents.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
voltage-gated Na⁺ currents 3	Inhibitor 8,297		52.1 µM [IC50]
Muscarinic acetylcholine receptor M1 169	Antagonist 2,778		1.2 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cough 106	Primary		Approved 8,429	SKF TUSS-ORNADE
Parkinson's disease 226	Primary		Approved 8,429	parpanit

Doses

Show entries

Dose	Population	Adverse events
20 mg single, oral	healthy, adult n = 30	Other AEs: Nausea, Dizziness...

Showing 1 to 1 of 1 entries

Previous1Next

AEs

Show entries

AE	Significance	Dose	Population
Dizziness	2 patients	20 mg single, oral	healthy, adult n = 30
Nausea	3 patients	20 mg single, oral	healthy, adult n = 30

Showing 1 to 2 of 2 entries

Previous1Next

Sourcing

Sourcing

Show entries

Vendor/Aggregator	ID	URL
001 Chemical	DY571133	https://www.001chemical.com/chem/77-22-5
Acorn PharmaTech	ACN-057466	http://www.acornpharmatech.com/
Aurora Fine Chemicals LLC	K02.797.422	http://online.aurorafinechemicals.com/info?ID=K02.797.422
ChemMol	99151441	http://www.chemmol.com/chemmol/99151441.html
Chemspace	CSSS00020619634	https://chem-space.com/CSSS00020619634

Showing 1 to 5 of 10 entries

Previous1 2Next

PubMed

Show entries

Title	Date	PubMed
Anticonvulsant efficacy of drugs with cholinergic and/or glutamatergic antagonism microinfused into area tempestas of rats exposed to soman.	2008 Feb	17710542
Efficacy of antidotal treatment against sarin poisoning: the superiority of benactyzine and caramiphen.	2008 Feb 15	18320638
Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats.	2008 Jun	18384867
Therapy against organophosphate poisoning: the importance of anticholinergic drugs with antiglutamatergic properties.	2008 Oct 15	18680758
Isobolographic analysis of caramiphen and lidocaine on spinal anesthesia in rats.	2010 Jan 18	19962431

Showing 1 to 5 of 5 entries

Previous1Next

Patents

Sample Use Guides

In Vivo Use Guide

2.5 to 6.0 mg/kg

Route of Administration: Intravenous

In Vitro Use Guide

It was investigated the effect of caramiphen (300uM) on voltage-gated sodium channels in differentiated neuronal NG108-15 cells. Caramiphen exhibited a milder state-dependence of block (IC₅₀ of 52.1 and 99.5 µM at holding potentials of -70 and -100 mV, respectively).

Show entries

Name

Type

Language

CARAMIPHEN EDISYLATE

Common Name

English

Caramiphen edisilate [WHO-DD]

Common Name

English

CARAMIPHEN EDISILATE

Common Name